IRON - Disc Medicine, Inc.
IEX Last Trade
65.08
-0.210 -0.323%
Share volume: 2,256
Last Updated: Thu 26 Dec 2024 08:29:52 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$65.29
-0.21
-0.32%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
1.88%
1 Month
3.77%
3 Months
35.30%
6 Months
49.76%
1 Year
6.57%
2 Year
4,094.19%
Key data
Stock price
$65.08
DAY RANGE
$64.01 - $65.90
52 WEEK RANGE
$27.04 - $77.60
52 WEEK CHANGE
$14.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Georges Gemayel
Region: US
Website: geminitherapeutics.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: geminitherapeutics.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Gemini Therapeutics, Inc. engages in developing therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) Its lead candidate is GEM103, a recombinant form of the human complement factor H protein. The company also develops GEM307 for treatment of systemic diseases.
Recent news